RLI Corp (RLI): what the price assumes

In the published model solve dated 2026-Q2, anchored at $62.81, RLI Corp (RLI) is priced for 17.9% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/RLI

Headline

FieldValue
TickerRLI
CompanyRLI Corp
Current price$62.81/sh
CompositionCasualty 59% / Property 32% / Surety 9%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed17.9%
Return on equity now22.7%
ROE gap-4.8pp
Price-to-book3.29x

Solve inputs: computed at a 8.2% cost of equity with 4% terminal growth over a 10-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~3.3pp.

Reconcile: at the x-ray's 9.3% required return this reads ~21.3%; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history-0.15σ
cohort percentile (of 88 peers)80
sustained it ~10 years at this level54%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.22x3expensive
Earnings1.22x1expensive
Relative0
Growth0.20x1justifies

Families that justify the price: Asset, Earnings, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=5)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowthno
Bank Fair Value (P/TBV)$87.280.72xyesTBVPS $18.51 × 4.71x (ROE (TTM) 25.0% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption))
Relative ValuationRelativenoP/E 11x (static sector reference · 2026-04), scenarios: 9.1x / 11.0x / 12.9x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowthno
Two-Stage DDMGrowth$308.680.20xyesStage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$51.461.22xyesBV/sh $19.01, ROE (TTM) 25.0%, ke 9.3%
Two-Stage Excess ReturnAsset$85.130.74xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowthnoRev $2.0B, growth 8% (input: historical growth; tapered), Terminal P/S: 2.4x / 2.9x / 3.4x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelativenoEPS $4.77, growth 35% (input: historical EPS growth), PEG=0.38 (Undervalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarningsno
Residual IncomeAssetno
Graham NumberAsset$45.171.39xyes√(22.5 × EPS $4.77 × BVPS $19.01) — Graham's conservative floor
EV/EBITDA RelativeRelativeno
FCF YieldEarningsno
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarningsnoEPS $4.77 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAssetno
P/Sales SectorRelativeno
PEG Fair ValueRelativenoEPS $4.77 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$51.571.22xyesEPS $4.77 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

The issuer is a funded financial business. Debt, interest, and cash flows are operating inputs, so industrial EV, net-debt, WACC, and free-cash-flow lenses do not apply; value the common-equity claim with book, earnings, capital, and payout economics.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Casualtyfinancialequity$954.0mwithheldunresolved standalone equity facts required
Propertyfinancialequity$512.4mwithheldunresolved standalone equity facts required
Suretyfinancialequity$148.0mwithheldunresolved standalone equity facts required

No unit-level total common-equity value is stated. Each financial unit requires supported standalone common equity, normalized earnings, capital adequacy, and payout capacity. Consolidated debt, interest, and cash are operating balances, not an enterprise-to-equity bridge; company-level book, earnings, capital, and payout lenses remain the coherent cross-checks.

Solvency

FieldValue
Share count CAGR (dilution)0.4%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

Set the price against the valuation methods and a clear picture emerges: RLI is expensive on the forward-growth lens but supported on the methods that reward demonstrated profitability. The book-value-plus-profitability methods land at or above the price, and the relative-multiple methods reach it, because they credit a return on equity of about 22 percent against a roughly 9 percent cost of that equity. That spread, earning more than double its cost of capital, is the entire bull case. An insurer that consistently earns far above its hurdle rate is worth a multiple of book, and the methods anchored on that reality support the current price even as the growth-only method calls it rich.

The profitability is not luck; it is a 30-year underwriting culture. RLI ran an 86 combined ratio in the first quarter, meaning it kept 14 cents of every premium dollar after claims and expenses before investment income even counts, and the segment detail shows where the edge lives. The 10-K reports the property segment earning $219 million of underwriting income on a 57.2 combined ratio in 2025, and the casualty expense ratio improving to 35.9 as earned premium outgrew expenses. Favorable development on prior-year reserves, which the filing quantifies segment by segment, is the mark of an underwriter that reserves conservatively and is proven right later. This is the opposite of a company buying growth with loose pricing.

The compounding shows up in the record and the ratings. RLI has raised its dividend for 50 consecutive years and earned underwriting profits for 30, and AM Best recently upgraded the insurance subsidiaries to A++ (Superior), the top tier, which directly supports the company's ability to write the specialty risks where pricing power lives. Net investment income rose more than 15 percent in the quarter to $42.3 million as higher reinvestment rates flow through the bond portfolio, adding a second profit engine alongside underwriting. A disciplined specialty insurer earning 20-plus percent on equity, top-rated for capital strength, with a half-century of rising dividends, is the kind of business where paying up for quality has historically been the cheaper mistake than waiting for it to get cheap.

Bear Case

The competitive reality of specialty insurance is that excess returns attract capital, and that is the heart of the bear case. RLI's roughly 23 percent return on equity is exceptional, but the lines it writes, niche casualty, property, and surety, are exactly where well-capitalized reinsurers and specialty peers redeploy when their own returns compress. RenaissanceRe, a peer in the same cohort, details in its FY2025 10-K an underwriting-expense ratio that "improved by 2.0 percentage points" as it sharpens its own economics, the kind of disciplined competitor that does not cede attractive niches quietly. When the broader insurance pricing cycle softens, as cycles always eventually do, the favorable reserve development and the 86 combined ratio that flatter today's results are the first things to fade, and a return on equity drifting from 23 percent back toward the mid-teens the price already assumes would be a normalization, not a disaster, but it would still cap the upside.

The valuation gives no room for that normalization. At roughly 2.7 times book, RLI sits at the very top of its peer group on price-to-book, a premium that prices in continued best-in-class returns. The first quarter already showed the direction of travel: net earnings fell to $54.9 million from $63.2 million a year earlier, and earnings per share slipped to $0.83 from $0.89, even with investment income rising. Underwriting and unrealized investment movements pressured the result, a reminder that a single elevated catastrophe quarter or a turn in the reserve cycle can swing earnings for a property-exposed writer.

The methods themselves flag the stretch. The forward-growth method reads the price as expensive, and the relative-multiple methods sit only modestly above it, which means the support comes almost entirely from the book-value-and-profitability lens, and that lens assumes today's elevated return on equity persists. History is the caution: of insurers earning this return, only about 58 percent sustained it for a decade. RLI may well be in that group, its record argues it is, but at the top price-to-book in the cohort, the buyer is paying for membership in advance, with little discount if the cycle, the competition, or a heavy catastrophe year says otherwise.

Valuation

An insurer is worth the return it earns on its capital, so RLI is read off price-to-book rather than an operating multiple. At today's price the market is paying about 2.7 times book and assuming the company sustains a return on equity near 16 percent, comfortably below the roughly 23 percent it has recently earned. On that arithmetic the assumption is not aggressive on the rate; the company is currently out-earning what the price requires. The stretch is that the price-to-book itself sits at the very top of the peer group, so the premium is paying for that out-earning to continue.

The methods sort into the value camp with one dissent. The book-value-plus-profitability methods, built on book value near $19.50 a share and a 22 percent return on equity, land at or above the price, and the relative-multiple methods reach it; only the forward-growth method reads the price as expensive. For a steadily profitable insurer that is the expected pattern, value lives in demonstrated returns, not in growth, and the growth method is the wrong lens for a business that compounds book value through underwriting discipline rather than rapid expansion.

For an insurer, the balance sheet is not corporate leverage; it is the float and capital that back the policies, and the relevant solvency read is capital strength and payout capacity. There the picture is unusually strong: AM Best rates the insurance subsidiaries A++, the share count is essentially flat, and the company has raised its dividend for 50 consecutive years, funded by 30 straight years of underwriting profit plus a growing investment-income stream now running above $42 million a quarter. The price is underwriting that the best-in-class return on equity holds; the financial strength is real and removes the downside-capital question, leaving the bet squarely on profitability persistence at a top-of-cohort price.

Catalysts

The first quarter combined a strong underwriting print with a year-over-year earnings step-down. RLI delivered an 86 combined ratio across its specialty portfolio, with net premiums earned up 3 percent to $411.4 million led by casualty, but net earnings fell to $54.9 million, or $0.83 per share, from $63.2 million, or $0.89, a year earlier. Net investment income rose 15.2 percent to $42.3 million, helping offset pressure from underwriting and unrealized investment movements during the quarter.

The rating action is the standout development. AM Best upgraded RLI's insurance subsidiaries to A++ (Superior) and the parent to a+ (Excellent), reinforcing the capital strength that underpins its ability to write specialty risk. The company also extended its long-running shareholder record, having paid and increased regular dividends for 50 consecutive years and delivered underwriting profits for 30. The signals to watch from here are the combined ratio trajectory as the pricing cycle matures, casualty premium growth, and whether reinvestment rates keep lifting investment income, the three levers that determine whether the top-of-cohort valuation is sustained.

Peer Cohorts (Per Segment, With Filing Citations)

Casualty (reported)

Property (reported)

Surety (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

RLI Q1 2026 results · RLI Q1 2026 8-K / AM Best upgrade

View the full interactive RLI report on boothcheck